Chengdu huasun technology group Past Earnings Performance
Past criteria checks 0/6
Chengdu huasun technology group's earnings have been declining at an average annual rate of -9.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 8% per year. Chengdu huasun technology group's return on equity is 2.8%, and it has net margins of 2.8%.
Key information
-9.9%
Earnings growth rate
-10.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 8.0% |
| Return on equity | 2.8% |
| Net Margin | 2.8% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses BreakdownBeta
How Chengdu huasun technology group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 962 | 27 | 331 | 32 |
| 31 Dec 23 | 1,003 | 28 | 307 | 32 |
| 30 Sep 23 | 939 | 36 | 279 | 20 |
| 30 Jun 23 | 949 | 39 | 276 | 18 |
| 31 Mar 23 | 886 | 36 | 264 | 21 |
| 31 Dec 22 | 873 | 41 | 270 | 25 |
| 30 Sep 22 | 1,009 | 47 | 270 | 22 |
| 30 Jun 22 | 1,024 | 50 | 270 | 22 |
| 31 Mar 22 | 1,013 | 53 | 260 | 23 |
| 01 Jan 22 | 955 | 56 | 282 | 18 |
| 30 Sep 21 | 778 | 42 | 286 | 15 |
| 30 Jun 21 | 785 | 38 | 303 | 22 |
| 31 Mar 21 | 779 | 43 | 318 | 19 |
| 31 Dec 20 | 759 | 38 | 320 | 20 |
| 30 Sep 20 | 755 | 39 | 319 | 27 |
| 30 Jun 20 | 715 | 47 | 335 | 18 |
| 31 Mar 20 | 718 | 56 | 347 | 23 |
| 31 Dec 19 | 745 | 62 | 359 | 23 |
| 30 Sep 19 | 727 | 68 | 366 | 25 |
| 30 Jun 19 | 712 | 59 | 372 | 35 |
| 31 Mar 19 | 659 | 38 | 360 | 27 |
| 31 Dec 18 | 633 | 31 | 343 | 27 |
| 30 Sep 18 | 616 | 240 | 318 | 25 |
| 30 Jun 18 | 594 | 170 | 303 | 22 |
| 31 Mar 18 | 622 | 173 | 283 | 21 |
| 31 Dec 17 | 591 | 172 | 255 | 17 |
| 30 Sep 17 | 612 | 10 | 255 | 10 |
| 30 Jun 17 | 595 | 77 | 232 | 0 |
| 31 Mar 17 | 592 | 80 | 244 | 0 |
| 31 Dec 16 | 575 | 82 | 247 | 0 |
| 30 Sep 16 | 511 | 41 | 246 | 0 |
| 30 Jun 16 | 459 | -25 | 259 | 0 |
| 31 Mar 16 | 451 | -36 | 255 | 0 |
| 31 Dec 15 | 463 | -37 | 250 | 0 |
| 30 Sep 15 | 499 | -9 | 256 | 0 |
| 30 Jun 15 | 500 | 57 | 207 | 0 |
| 31 Mar 15 | 525 | 64 | 206 | 0 |
| 31 Dec 14 | 528 | 66 | 202 | 0 |
| 30 Sep 14 | 576 | 43 | 184 | 0 |
| 30 Jun 14 | 642 | 44 | 190 | 0 |
| 31 Mar 14 | 616 | 48 | 161 | 0 |
| 31 Dec 13 | 658 | 50 | 164 | 0 |
| 30 Sep 13 | 655 | 39 | 169 | 0 |
| 30 Jun 13 | 626 | 42 | 173 | 0 |
Quality Earnings: 000790 has a large one-off loss of CN¥8.2M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 000790's current net profit margins (2.8%) are lower than last year (4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000790's earnings have declined by 9.9% per year over the past 5 years.
Accelerating Growth: 000790's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 000790 had negative earnings growth (-25.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.5%).
Return on Equity
High ROE: 000790's Return on Equity (2.8%) is considered low.